A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

Semmelweis University Medical School, Budapest

National Medical Center, Budapest

Cliniques Universitaires Saint Luc, Brussels

UZ Gasthuisberg, Leuven

1st School of Medicine, Charles University, Prague

Karolinska Sjukhuset, Stockholm

Università degli Studi di Ferrara, Ferrara

Università degli Studi di Milano, Milan

Endokrinologiska kliniken, Malmo

Ospedali Riuniti di Bergamo, Bergamo

Clínica Puerta de Hierro, Madrid

Fundación Jiménez Díaz, Madrid

CHU de Rangueil, Toulouse

Hôpital du Haut-Lévêque, Pessac

Research Centre for Endocrinology and Metabolism, Gothenburg

Hôpital de la Timone, Marseille

CHU de Liege, Liège

Centre Hospitalier Régional d'Orléans, Orléans

Dipartimento di Scienze, Endocrinologiche e Metaboliche, Genova

University Hospital, Charles University, Kralove

Hôpital Maison Blanche, Reims

CHU de Brabois, Nancy

Hôpital de Bois, Bois-Guillaume

"University Federico II of Naples", Naples

National University Hospital, Copenhagen

Clinica Medica II, Roma

Bielanski Hospital, Warsaw

Hospital General de Alicante, Alicante

Queen Elizabeth Medical Centre, Edgbaston

Royal Free Hospital, Hampstead

Michael White Diabetes Centre, Hull

Christie Hospital, Manchester

Northern General Hospital, Sheffield